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Introduction:COVID-19 is associated with a novel multi-system inflammatory syndrome
that shares some characteristics with Kawasaki’s Disease. The syndromemanifestation is
delayed relative to COVID-19 onset, with a spectrum of clinical severity. Clinical signs may
include persistent fever, gastrointestinal symptoms, cardiac inflammation and/or shock.
Case Presentation: We measured 59 inflammatory and endothelial injury plasma
analytes in an adolescent girl that presented with malaise, fever, cough, strawberry
tongue and jaundice. Her COVID-19 status was positive with detection of 2 SARS-CoV-2
viral genes using polymerase chain reaction. She was treated with intravenous
immunoglobulin prior to blood draw, but our plasma measurements suggested a
unique analyte expression pattern associated with inflammation, endothelial injury and
microvascular glycocalyx degradation.
Conclusions: COVID-19 is associated with a multi-system inflammatory syndrome and
a unique inflammatory and endothelial injury signature.
Summary: Analyte markers of inflammation and endothelial cell injury might serve as
putative biomarkers and/or be investigated further as potential therapeutic targets.
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INTRODUCTION
COVID-19 has been associated with a novel multisystem inflammatory syndrome in children
(1, 2). Presentation is typically delayed after SARS-CoV-2 exposure, with clinical symptoms that
share features of Kawasaki’s Disease (KD) (3). A “cytokine storm” has been suggested to underlie
the syndrome, with tissue injury secondary to the host innate response (4). The inflammatory
and endothelial injury mediators have been described for adult COVID-19 patients (5–8), but
knowledge of these analytes in COVID-19 children is limited and may be critically important for
earlier syndrome recognition and for potential interventions. Furthermore, inflammatory analyte
pediatric reference standards for healthy control comparisons are generally unavailable.
PATIENT INFORMATION
A 15-year-old female presented to hospital to a tertiary care emergency department with a history
of malaise, dry cough, strawberry tongue, rash and jaundice. COVID19 was confirmed by detection
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of two SARS-CoV-2 viral genes using polymerase chain reaction.
Her complete blood count, electrolytes, coagulation profile and
blood gas were normal. C-reactive protein and ferritin were
mildly elevated at 25.7 mg/L and 302 µg/L, respectively. She
had a mild hepatitis with alanine aminotransferase 142 U/L,
aspartate aminotransferase 87 U/L, alkaline phosphate 405 U/L,
total bilirubin 92.6 µmol/L. She was admitted to hospital
with a presumptive diagnosis of atypical KD and treated with
intravenous immunoglobulin (IVIg) and Aspirin. Her inpatient
electrocardiogram and echocardiogram were normal.
Blood was drawn for inflammation/endothelial injury
profiling after the patient’s COVID-19 status was confirmed, but
IVIg had already been administered approximately 48 h earlier.
Thus, analyte measurements must be evaluated in the context of
this immune modulator (see below). Nonetheless, we measured
59 inflammation- and endothelium-related analytes using
multiplexed biomarker immunoassay kits or enzyme-linked
immunosorbent assay (ELISA). As only one COVID-19 pediatric
patient was admitted to our hospital, we compared the measured
analyte values from this COVID-19 case patient to analyte
reference ranges that we obtained from a cohort of 20 pediatric
healthy control subjects [median 15 years of age (IQR 8)].
The analyte data from the COVID-19 patient and the 20
healthy control subjects were first visualized with a nonlinear
dimensionality reduction on the full data matrix using the
t-distributed stochastic nearest neighbor (t-SNE) embedding
algorithm (Figure 1) (9). t-SNE assumes that the “optimal”
representation of the data lies on a manifold with complex
geometry, but low dimension, embedded in the full dimensional
FIGURE 1 | The COVID-19 case patient and 20 healthy control subjects plotted in two dimensions following dimensionality reduction by stochastic neighbor
embedding. The Purple dot represents the COVID-19 patient, while the yellow dots represent the healthy controls. The dimensionality reduction shows that based on
59 plasma analyte concentrations, the COVID-19 patients is distinct and easily separable. The axes are dimension-less.
space of the raw data. Based on analyte measurements, the
COVID-19 case patient is a clear outlier with respect to her
inflammation and endothelial injury profile.
We then generated confidence intervals (CIs) for the expected
value of each analyte using the plasma measurements from the
20 healthy pediatric controls. The plasma values for each analyte
were not normally distributed, so we computed 99.9% (95%,
Bonferonni corrected for comparison across 59 plasma analytes)
CIs via the bias corrected and accelerated bootstrap. Plasma
analyte values in the COVID-19 case patient that were outside
the CIs for healthy control subjects were therefore considered
significant (p < 0.05, corrected; Table 1). We found significant
elevations in 21 inflammation and endothelial analyte markers,
while 1 endothelial glycocalyx degradation marker (heparan
sulfate) was significantly depressed (Table 1).
After 3 days of observation, and partial resolution of her
symptoms, our COVID-19 case patient was discharged home
on Aspirin (3 mg/kg/day). Follow-up appointments at 2- and
6-weeks post-discharge revealed resolving hepatitis and both
electrocardiograms and echocardiograms were normal with no
evidence of coronary aneurysm. The aspirin was discontinued at
the 6-week follow-up appointment.
DISCUSSION
We present an COVID-19 positive adolescent female with a
unique analyte expression pattern associated with inflammation,
endothelial injury and microvascular glycocalyx degradation.
Given the timing of the blood draw, some plasma analytes may
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TABLE 1 | Significant analyte concentration changes for the COVID-19 case
patient and 20 healthy control subjects (EC, endothelial cell).
Plasma analyte Units 20 healthy controls
(CI: 5%, 95%)
Case patient
1. MMP7 pg/ml 3,356, 4,424 51,788
2. IP-10 pg/ml 86, 242 1,098
3. Resistin pg/ml 7.3, 11.1 41.8
4. IL-3 pg/ml 0.1, 2.4 7.3
5. Hyaluronic acid (EC) ng/ml 17.6, 40.4 119.2
6. Thrombospondin-1 pg/ml 620, 1,275 3,286
7. Elastase 2 pg/ml 2.1, 4.4 11.3
8. PDGF-AB/BB pg/ml 769, 2,537 6,390
9. MIG pg/ml 1,205, 2,684 6,531
10. MCP-1 pg/ml 190.3, 269.5 529.4
11. MMP1 pg/ml 384, 709 1,286
12. Lactoferrin pg/ml 338.3, 521.3 845.8
13. IL-1RA pg/ml 8.1, 73.3 112.0
14. IL-18 pg/ml 30.3, 64.6 98.3
15. IFNα2 pg/ml 13.2, 120.7 179.6
16. sP-selectin (EC) ng/ml 16.3, 22.4 30.4
17. MIP-1β pg/ml 22.8, 72.0 89.16
18. Eotaxin pg/ml 49.4, 81.6 97.4
19. MMP8 pg/ml 288.4, 643.6 762.7
20. PDGF-AA pg/ml 84.4, 652.9 766.8
21. MMP10 pg/ml 385.2, 751.4 876.1
22. Heparan sulfate (EC) ng/ml 22.7, 294.5 20.6
The data is in rank order of magnitude of change.
have been altered by IVIg administration or down-regulated to
the levels of healthy control subjects. Nonetheless, we briefly
summarize the purported actions of the top five analytes that
were elevated 3-fold or greater in the COVID-19 case patients
relative to the upper confidence limit for healthy controls, and
we compare these findings to published reports of IVIg-treated
KD patients (10–13).
Matrix metalloproteinase 7 (MMP7) was the most elevated
analyte in the COVID-19 case patient relative to healthy
control subjects. Also called matrilysin, MMP7 is expressed
in endothelial cells, monocytes and macrophages and it
is capable of degrading multiple extracellular membrane
components (proteoglycans, laminin, fibronectin, casein and
basement membrane collagen type IV). MMP7 is significantly
upregulated in KD and it is implicated in acute vasculopathy
(14). Specifically, MMP7 degrades endothelial junctions,
which can promote vascular leak/edema and/or leukocyte
migration into tissues (15). A variety of circulating MMPs are
elevated in KD, with plasma levels decreasing following IVIg
therapy (16).
Interferon-γ-inducible protein 10 (IP-10), an inflammatory
cytokine secreted primarily by monocytes and endothelial cells in
response to interferon-γ (IFN γ), was also significantly elevated
in the COVID-19 case patient. IP-10 has multiple roles including
lymphocyte chemoattraction and adhesion to endothelial cells.
IP-10 is a promising target for the treatment of infectious
diseases as it aids cellular targeting to threatened tissues where
it modulates innate and adaptive immune responses. High
serum IP-10 is found in KD, and it has been suggested as
a KD biomarker (11). IP-10 levels remain elevated after IVIg
treatment in some refractory KD patients (10), while in others,
IP-10 slowly decreased to control levels by 1-week post-IVIg
administration (11).
Resistin is highly expressed inmacrophages, bonemarrow and
the non-fat fraction of adipose tissue, and it stimulates several
pro-inflammatory pathways and cytokines. Microvascular tone,
as well as endothelial cell barrier function and nitric oxide
production, are all altered by resistin. Similar to our COVID-19
case patient, elevated resistin is found in plasma fromKDpatients
(17, 18). Post-IVIg therapy, 3–5 days, plasma resistin levels in KD
patients significantly decreased (12).
Interleukin 3 (IL-3), released by activated T-cells, was elevated
in our COVID-19 case patient. IL-3 promotes the production of
inflammatory monocytes and neutrophils, thereby contributing
to the cytokine storm that is implicated in sepsis from
multiple etiologies. The microvascular endothelial cell response
to inflammation and immunity is also regulated by IL-3 (19) and
vasculopathy is suggested to be a primary feature of the novel
multi-system inflammatory syndrome. IVIg treatment decreases
IL-3 production by activated T-cells and monocyte/macrophage
to control levels within 72 h (20).
Hyaluronic acid is a major constituent of the microvascular
glycocalyx, an extracellular matrix that coats the luminal
surface of the endothelium (21). Hyaluronic acid degradation
products are significantly elevated in plasma from the
COVID-19 case patient, suggesting that the microvascular
endothelial cell luminal surface has been pathologically
altered. Disruption of the endothelial glycocalyx is
associated with vascular lesions and barrier dysfunction
in KD (13), as well as decreased endothelial nitric oxide
production and increased platelet/endothelium adhesion
(21), Endothelial cell injury was supported in the COVID-19
case patient by the parallel elevation of soluble P-selectin,
an endothelial/platelet glycoprotein that mediates adhesive
intercellular interactions (22). Elevated plasma hyaluronic acid
found in KD patients slowly decreases after IVIg treatment,
normalizing at the time of discharge in the convalescent
phase (13).
Our measurements showed minimal alterations in 37
inflammation and endothelial analyte markers: epidermal
growth factor (EGF), granulocyte-colony stimulating factor
(G-CSF), granulocyte-macrophage colony-stimulating factor
(GM-CSF), IFNγ, interleukin 1a (IL-1a), IL-1b, IL-2, IL-4,
IL-5, IL-6, IL-7, IL-8, IL-10, IL-12(p40), IL-12(p70), IL-
13, IL-15, IL-17a, IL17e/IL25, IL-17f, IL-22, macrophage
colony-stimulating factor (M-CSF), macrophage inflammatory
protein 1α (MIP-1α, tumor necrosis factor α (TNFα), TNFβ,
vascular endothelial growth factor A (VEGFA), regulated
upon activation, normal T Cell expressed and presumably
secreted (RANTES), MMP2, MMP3, MMP9, MMP12,
MMP13, neutrophil gelatinase-associated lipocalin (NGAL),
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Granzyme B, heat shock protein 70 (HSP-70), chondroitin
sulfate and syndecan-1. As some of these measurements
may have been depressed by IVIg administration (23), no
significant conclusions can be made with regards to their
pre-treatment level. It is also plausible that some inflammatory
analytes were transiently increased with inflammation onset,
with TNF and IL-6 as typical examples (24). TNF-α is a
pro-inflammatory cytokine released primarily by monocytes
and macrophages that enhances the adaptive immune response.
IL-6 is produced by monocytes and macrophages, and induces
T-cell activation, B cell proliferation and stimulates the acute
phase reaction, all of which lead to augmentation of the
immune response.
CONCLUSION
Pediatric COVID-19 patients can present with a novel
multisystem inflammatory syndrome with some clinical
features similar to KD. The analyte measurements presented
in this study, albeit post IVIg treatment, support a systemic
inflammatory process that resulted in significant endothelial
injury. The elevated analyte measurements are similar to KD
patients whom had also received IVIg therapy. These data
should aid future hypothesis-generating research, as some of the
identified analytes might be putative disease biomarkers and/or
potential therapeutic targets. Age-matched healthy control
analyte reference values are included and will be valuable for
future studies.
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